Lacosamide Shows Benefit in Partial-Onset Seizures
Study finds reduced seizure frequency with lacosamide as adjunctive treatment
MONDAY, March 8 (HealthDay News) -- The use of lacosamide as an adjunctive treatment in patients with uncontrolled partial-onset seizures is effective in reducing seizure frequency and may provide additional benefits for some patients with secondarily generalized tonic-clonic seizures, according to research published online Jan. 27 in Epilepsia.
Steve Chung, M.D., of the Barrow Neurological Institute in Phoenix, and colleagues analyzed data from 405 patients, aged 16 to 70 years, who were taking one to three antiepileptic drugs but had uncontrolled partial-onset seizures. Subjects in this phase III trial were randomized to receive placebo or 400 or 600 mg of lacosamide daily. The study included an eight-week baseline period, a six-week titration period, and 12 weeks of maintenance.
The researchers found that the treatment groups had greater reductions in seizure frequency per 28 days from baseline to maintenance compared to placebo (37.3 percent for 400 mg, 37.8 percent for 600 mg, and 20.8 percent for placebo). Patients taking 400 and 600 mg dosages of lacosamide had 59.4 and 93 percent reductions, respectively, in the frequency of secondarily generalized tonic-clonic seizures, compared to 14.3 percent for the placebo group.
"Adjunctive treatment with lacosamide 400 and 600 mg/day reduced seizure frequency for patients with uncontrolled partial-onset seizures," the authors conclude. "Lacosamide 400 mg/day provided a good balance of efficacy and tolerability; lacosamide 600 mg/day may provide additional benefit for some patients as suggested by secondary efficacy analyses, including response in patients with secondarily generalized tonic-clonic seizures."
The authors reported various consulting relationships with pharmaceutical and medical device companies. The UCB group sponsored and funded the trial.